Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 20

Sort by

Sort Order Select

Journal Articles

Phase 3 Randomized Study of Daratumumab (DARA) + Bortezomib, Lenalidomide and Dexamethasone (VRd) Versus Alone in Patients with Transplant-Ineligible Newly Diagnosed Multiple Myeloma or for Whom Transplant Is Not Planned As Initial Therapy: Analysis of Minimal Residual Disease in the Cepheus Trial

Blood (2024) 144 (Supplement 1): 362.

https://doi.org/10.1182/blood-2024-200871

Published: 2024

Journal Articles

Real-Life Use of Asciminib in Patients with Chronic Myeloid Leukemia in Chronic Phase (CML-CP): Results of the Turkish Managed Access Program

Blood (2024) 144 (Supplement 1): 6588.

https://doi.org/10.1182/blood-2024-202019

Published: 2024

Journal Articles

Real-Life Outcomes of Bosutinib in Patients with Chronic Myeloid Leukemia: A Multicenter Nationwide Study from Turkey

Serkan Guven, Deniz Özmen, Yunus Çatma, Tuba Güllü Koca, Onur Kırkızlar, Ömer Şeker, Sercan Ünal, Seçil Salim, Betül Kübra Tüzün, Aslı Yüksel Öztürkmen, Nergiz Erkut, Esra Kiriktir, Nesibe Taşer Kanat, Püsem Patır, Abdülkadir Karışmaz, Seval Akpınar, Emel Gürkan, Nurcan Özçelik Kürkçü, Öznur Aydın, Gülsüm Çağlıyan, Ayfer Gedük, Süleyman Arslan, Zehra Narlı Özdemir, Rafiye Çiftçiler, Ayşe Uysal, Merve Aydoğan, Yıldız İpek, Merve Ecem Erdoğan Yön, Zeynep Tuğba Karabulut, Emel Bostan, Sinan Mersin, Tarık Onur Tiryaki, Vildan Gürsoy, İrfan Yavaşoğlu, Ali Doğan, Güchan Alanoğlu, Mehmet Baysal, Eren Arslan Davulcu, Ayşe Kaya, İbrahim Ethem Pınar, Abdülkerim Yıldız, Gülşah Akyol, İnci Alacacıoğlu, Mutlu Arat, Mesut Ayer, Meltem Aylı, İlhami Berber, Ahmet Muzaffer Demir, İbrahim Haznedaroğlu, Fehmi Hindilerden, Erdal Kurtoğlu, Meliha Nalçacı, Fahir Özkalemkaş, Vildan Özkocaman, Güray Saydam, Mehmet Sönmez, Selami Koçak Toprak, Tülin Tuğlular, Burhan Turgut, Mehmet Turgut, Ahmet Emre Eskazan

Blood (2024) 144 (Supplement 1): 6585.

https://doi.org/10.1182/blood-2024-193433

Published: 2024

Journal Articles

Zilovertamab Vedotin in Combination with Nemtabrutinib for Patients with Relapsed or Refractory Mantle Cell Lymphoma: Cohort C of the Open-Label, Phase 2 Waveline-006 Study

Ewa Paszkiewicz-Kozik, Claudia Moreira, Mehmet Turgut, Marcelo Garrido, Ingrid Glimelius, Seung Tae Lee, Yazeed Sawalha, Yixin Ren, Katherine Ryland, Uzor C. Ogbu, Diego Villa

Blood (2024) 144 (Supplement 1): 3025.

https://doi.org/10.1182/blood-2024-205985

Published: 2024

Journal Articles

Primary Results of Stimulus-MDS1: A Randomized, Double-Blind, Placebo-Controlled Phase II Study of TIM-3 Inhibition with Sabatolimab Added to Hypomethylating Agents (HMAs) in Adult Patients with Higher-Risk Myelodysplastic Syndromes (MDS)

Amer M. Zeidan, Kiyoshi Ando, Odile Rauzy, Mehmet Turgut, Ming-Chung Wang, Roberto Cairoli, Hsin-An Hou, Yok-Lam Kwong, Montserrat Arnan Sangerman, Stef Meers, Vinod A. Pullarkat, Valeria Santini, Kamel Malek, Flavia Kiertsman, Jiaying Lyu, Pedro Marques Ramos, Pierre Fenaux, Yasushi Miyazaki, Uwe Platzbecker

Blood (2022) 140 (Supplement 1): 2063–2065.

https://doi.org/10.1182/blood-2022-158612

Published: 2022

Journal Articles

Efficacy and Safety of Eltrombopag Combined with Cyclosporine As First-Line Therapy in Adults with Severe Acquired Aplastic Anemia: Results of the Interventional Phase 2 Single-Arm Soar Study

Carlos Vallejo, Jun Ho Jang, Carlo Finelli, Efreen Montaño Figueroa, Lalita Norasetthada, Rodrigo T. Calado, Mehmet Turgut, Regis Peffault De Latour, Ulrike Kriemler-Krahn, Jens Haenig, Joan Maier, Phillip Scheinberg

Blood (2021) 138 (Supplement 1): 2174.

https://doi.org/10.1182/blood-2021-147733

Published: 2021

Journal Articles

Evaluation of Minimal Residual Disease (MRD) Negativity in Patients with Relapsed or Refractory Multiple Myeloma Treated in the Candor Study

Ola Landgren, MD PhD, Katja Weisel, MD, Laura Rosinol Dachs, Philippe Moreau, MD, Mehmet Turgut, MD, Roman Hajek, MD PhD, Peter Mollee, FRACP,MBBS,MSc,FRCPA, Jin Seok Kim, MD PhD, Jianqi Zhang, Ning Go, PhD, Christopher L. Morris, PhDMD, Saad Z. Usmani, MDMBBS,MBA

Blood (2020) 136 (Supplement 1): 32–34.

https://doi.org/10.1182/blood-2020-141291

Published: 2020

Journal Articles

Evolving Unmet Need in Patients Refractory to Lenalidomide: Overview of the Clinical Trials in Relapsed/Refractory Multiple Myeloma

Maria-Victoria Mateos, MD PhD, Rohan Medhekar, PhD, Istvan Majer, PhD, Mehmet Turgut, MD

Blood (2020) 136 (Supplement 1): 22–23.

https://doi.org/10.1182/blood-2020-142642

Published: 2020

Journal Articles

Isatuximab Plus Carfilzomib and Dexamethasone Versus Carfilzomib and Dexamethasone in Relapsed Multiple Myeloma Patients with Renal Impairment: Ikema Subgroup Analysis

Marcelo Capra, MD PhD, Thomas Martin, III, MD, Philippe Moreau, MD, Ross Baker, MBBS, FRACP, FRCPA, BSc, Ludek Pour, MD, Chang-Ki Min, MD PhD, Xavier Leleu, MD, Mohamad Mohty, MD PhD, Marta Reinoso Segura, Mehmet Turgut, MD, Richard Leblanc, MD FRCPC, Marie-Laure Risse, Laure Malinge, Sandrine Schwab, Meletios A Dimopoulos

Blood (2020) 136 (Supplement 1): 46–47.

https://doi.org/10.1182/blood-2020-136415

Published: 2020

Journal Articles

Delays in Time to Deterioration of Health-Related Quality of Life Were Observed in Patients with Acute Myeloid Leukemia Receiving Venetoclax in Combination with Azacitidine or in Combination with Low-Dose Cytarabine

Blood (2020) 136 (Supplement 1): 33–35.

https://doi.org/10.1182/blood-2020-133912

Published: 2020

Journal Articles

The QUAZAR AML-001 Maintenance Trial: Results of a Phase III International, Randomized, Double-Blind, Placebo-Controlled Study of CC-486 (Oral Formulation of Azacitidine) in Patients with Acute Myeloid Leukemia (AML) in First Remission

Blood (2019) 134 (Supplement_2): LBA-3.

https://doi.org/10.1182/blood-2019-132405

Published: 2019

Journal Articles

Analysis of Elderly Patients with Chronic Myeloid Leukemia

Engin Kelkitli, MD, Hakan Goker, MD, Mehmet Turgut, MD, Memis Hilmi Atay, MD

Blood (2018) 132 (Supplement 1): 5449.

https://doi.org/10.1182/blood-2018-99-110222

Published: 2018

Journal Articles

Multicenter Early Access Program Results from Turkey: Efficacy and Safety of Daratumumab Among Heavily Pretreated Relapse/Refractory Multiple Myeloma Patients

Meral Beksac, MD, Yildiz Aydin, MD, Hakan Goker, MD, Mehmet Turgut, MD, Sevgi Kalayoglu Besisik, Seckin Cagirgan, Tulin F Tuglular, MD, Filiz Vural, MD, Munci Yagci, MD

Blood (2017) 130 (Supplement 1): 5442.

https://doi.org/10.1182/blood.V130.Suppl_1.5442.5442

Published: 2017

Journal Articles

Real-World Data in Relapsed Refractory Myeloma Patients Treated with Carfilzomib, a Multicenter Turkish Experience

Blood (2017) 130 (Supplement 1): 5405.

https://doi.org/10.1182/blood.V130.Suppl_1.5405.5405

Published: 2017

Journal Articles

Safety and Efficacy of Obinutuzumab Plus Fludarabine and Cyclophosphamide in Previously Untreated Patients with Chronic Lymphocytic Leukemia: Subgroup Analysis of the GREEN Study

Veronique Leblond, Guy Cantin, MD, Agostino Cortelezzi, Prof, Wolfgang Knauf, Mourad Tiab, Mehmet Turgut, MD, Andrey Zaritskey, Jean-Louis Merot, Kerstin Trunzer, Susan Robson, Ekaterina Gresko, Stephan Stilgenbauer, MD PhD, Robin Foà, Francesc Bosch

Blood (2017) 130 (Supplement 1): 3015.

https://doi.org/10.1182/blood.V130.Suppl_1.3015.3015

Published: 2017

Journal Articles

Splenic Marginal Zone Lymphoma in an East Mediterranean/Middle Eastern Population Cohort: Possible Association with Hepatitis B Instead of Hepatitis C Virus As an Etiologic and Prognostic Factor (ThREG-NHL01 Study)

Tuncay Aslan, Evren Ozdemir, MD, Aysegul Uner, Elif Gungor, Nevin Alayvaz Aslan, Esra Yildizhan, MD, Abdullah Agit, Serdal Korkmaz, MD, Gulsum Akgun Cagliyan, Ibrahim Barista, MD, Esra Ozhamam, Gulsum Emel Pamuk, MD, Mehmet Turgut, MD PhD, Bulent Eser, Gulsum Ozet, MD, Rahsan Yıldırım, Yahya Buyukasik, MD

Blood (2016) 128 (22): 5332.

https://doi.org/10.1182/blood.V128.22.5332.5332

Published: 2016

Journal Articles

An Open-Label Phase II Study of Buparlisib (BKM120) in Patients with Relapsed and Refractory Diffuse Large B-Cell Lymphoma (DLBCL), Mantle Cell Lymphoma (MCL) and Follicular Lymphoma (FL)

Anas Younes, MD, Gilles Salles, Giovanni Martinelli, R. Gregory Bociek, MD, Dolores Caballero Barrigon, MD, Eva Gonzalez Barca, Mehmet Turgut, MD PhD, John F. Gerecitano, MD, Fabian Herbst, Lisa Williams, Nabanita Mukherjee, Ranjana Tavorath, Won Seog Kim, MD PhD

Blood (2015) 126 (23): 1493.

https://doi.org/10.1182/blood.V126.23.1493.1493

Published: 2015

Journal Articles

Preliminary Safety Results from the Phase IIIb GREEN Study of Obinutuzumab (GA101) Alone or in Combination with Chemotherapy for Previously Untreated or Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL)

Francesc Bosch, MD PhD, Thomas Illmer, MD, Mehmet Turgut, MD PhD, Agostino Cortelezzi, MD, Susan F. Lasserre, MSc, Anna Truppel-Hartmann, MD, Veronique Leblond, MD PhD, Robin Foà, MD, Stephan Stilgenbauer, MD

Blood (2014) 124 (21): 3345.

https://doi.org/10.1182/blood.V124.21.3345.3345

Published: 2014

Journal Articles

Antiphospholipid antibodies and antiphospholipid syndrome in patients presenting with immune thrombocytopenic purpura: a prospective cohort study

Reyhan Diz-Küçükkaya, Abdullah Hacıhanefioǧlu, Mustafa Yenerel, Mehmet Turgut, Hüseyin Keskin, Meliha Nalçacı, Murat l˙nanç

Blood (2001) 98 (6): 1760–1764.

https://doi.org/10.1182/blood.V98.6.1760

Published: 2001

Journal Articles

CD15-expressing phagocytic plasma cells in a patient with multiple myeloma

Reyhan Diz Kucukkaya, Abdullah Hacihanefioglu, Mustafa Nuri Yenerel, Mehmet Turgut, Meliha Nalcaci, Huseyin Keskin, Seyhun Solakoglu, Gulderen Yanikkaya Demirel

Blood (2001) 97 (2): 581–583.

https://doi.org/10.1182/blood.V97.2.581

Published: 2001

NARROW

Phase 3 Randomized Study of Daratumumab (DARA) + Bortezomib, Lenalidomide and Dexamethasone (VRd) Versus Alone in Patients with Transplant-Ineligible Newly Diagnosed Multiple Myeloma or for Whom Transplant Is Not Planned As Initial Therapy: Analysis of Minimal Residual Disease in the Cepheus Trial

Real-Life Use of Asciminib in Patients with Chronic Myeloid Leukemia in Chronic Phase (CML-CP): Results of the Turkish Managed Access Program

Real-Life Outcomes of Bosutinib in Patients with Chronic Myeloid Leukemia: A Multicenter Nationwide Study from Turkey

Zilovertamab Vedotin in Combination with Nemtabrutinib for Patients with Relapsed or Refractory Mantle Cell Lymphoma: Cohort C of the Open-Label, Phase 2 Waveline-006 Study

Primary Results of Stimulus-MDS1: A Randomized, Double-Blind, Placebo-Controlled Phase II Study of TIM-3 Inhibition with Sabatolimab Added to Hypomethylating Agents (HMAs) in Adult Patients with Higher-Risk Myelodysplastic Syndromes (MDS)

Efficacy and Safety of Eltrombopag Combined with Cyclosporine As First-Line Therapy in Adults with Severe Acquired Aplastic Anemia: Results of the Interventional Phase 2 Single-Arm Soar Study

Evaluation of Minimal Residual Disease (MRD) Negativity in Patients with Relapsed or Refractory Multiple Myeloma Treated in the Candor Study

Evolving Unmet Need in Patients Refractory to Lenalidomide: Overview of the Clinical Trials in Relapsed/Refractory Multiple Myeloma

Isatuximab Plus Carfilzomib and Dexamethasone Versus Carfilzomib and Dexamethasone in Relapsed Multiple Myeloma Patients with Renal Impairment: Ikema Subgroup Analysis

Delays in Time to Deterioration of Health-Related Quality of Life Were Observed in Patients with Acute Myeloid Leukemia Receiving Venetoclax in Combination with Azacitidine or in Combination with Low-Dose Cytarabine

The QUAZAR AML-001 Maintenance Trial: Results of a Phase III International, Randomized, Double-Blind, Placebo-Controlled Study of CC-486 (Oral Formulation of Azacitidine) in Patients with Acute Myeloid Leukemia (AML) in First Remission

Analysis of Elderly Patients with Chronic Myeloid Leukemia

Multicenter Early Access Program Results from Turkey: Efficacy and Safety of Daratumumab Among Heavily Pretreated Relapse/Refractory Multiple Myeloma Patients

Real-World Data in Relapsed Refractory Myeloma Patients Treated with Carfilzomib, a Multicenter Turkish Experience

Safety and Efficacy of Obinutuzumab Plus Fludarabine and Cyclophosphamide in Previously Untreated Patients with Chronic Lymphocytic Leukemia: Subgroup Analysis of the GREEN Study

Splenic Marginal Zone Lymphoma in an East Mediterranean/Middle Eastern Population Cohort: Possible Association with Hepatitis B Instead of Hepatitis C Virus As an Etiologic and Prognostic Factor (ThREG-NHL01 Study)

An Open-Label Phase II Study of Buparlisib (BKM120) in Patients with Relapsed and Refractory Diffuse Large B-Cell Lymphoma (DLBCL), Mantle Cell Lymphoma (MCL) and Follicular Lymphoma (FL)

Preliminary Safety Results from the Phase IIIb GREEN Study of Obinutuzumab (GA101) Alone or in Combination with Chemotherapy for Previously Untreated or Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL)

Antiphospholipid antibodies and antiphospholipid syndrome in patients presenting with immune thrombocytopenic purpura: a prospective cohort study

CD15-expressing phagocytic plasma cells in a patient with multiple myeloma

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only